Literature DB >> 2251521

Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease.

M Henry-Amar1, R Somers.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2251521

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  17 in total

Review 1.  Current therapies in Hodgkin's disease.

Authors:  K E Kogel; J W Sweetenham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-30       Impact factor: 9.236

Review 2.  Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?

Authors:  D J Dodwell; E S de Campos; J A Radford
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 3.  Hodgkin's lymphoma. II: Treatment and delayed morbidity.

Authors:  P Carde
Journal:  BMJ       Date:  1992-07-18

4.  The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG).

Authors:  Ljubomir R Jakovic; Biljana S Mihaljevic; Maja D Perunicic Jovanovic; Andrija D Bogdanovic; Vesna M Cemerikic Martinovic; Tamara K Kravic; Vladimir Z Bumbasirevic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 5.  Hodgkin's disease--I: Identification and classification.

Authors:  P Carde
Journal:  BMJ       Date:  1992-07-11

6.  A 26-year-old man with Hodgkin's disease and rapidly progressive pancytopenia.

Authors:  J C Kluin-Nelemans; P M Kluin; R Bieger
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

7.  [Second malignancies after the therapy of Hodgkin's disease: the Freiburg collective 1940 to 1991].

Authors:  J Slanina; F Heinemann; K Henne; G Moog; H Frommhold
Journal:  Strahlenther Onkol       Date:  1999-04       Impact factor: 3.621

8.  Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors.

Authors:  Aileen B Chen; Rinaa S Punglia; Karen M Kuntz; Peter M Mauch; Andrea K Ng
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

9.  Efficacy of dose escalation on TCP, recurrence and second cancer risks: a mathematical study.

Authors:  V S K Manem; A Dhawan; M Kohandel; S Sivaloganathan
Journal:  Br J Radiol       Date:  2014-09-11       Impact factor: 3.039

10.  Modelling recurrence and second cancer risks induced by proton therapy.

Authors:  V S K Manem; A Dhawan
Journal:  Math Med Biol       Date:  2018-09-11       Impact factor: 1.854
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.